Research Output per year
Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 5 Similar Profiles
Apoptosis
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medicine & Life Sciences
Phosphotransferases
Medicine & Life Sciences
Tumors
Chemical Compounds
Cell Death
Medicine & Life Sciences
DNA Damage
Medicine & Life Sciences
Death Domain Receptors
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1993 2018
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., Artemov, A. V., Wysocki, P. T., Mehra, R., Nimmagadda, S., Marchionni, L., Sidransky, D., Borrello, I. M., Izumchenko, E. & Bedi, A., Dec 1 2018, In : Nature Communications. 9, 1, 741Research output: Contribution to journal › Article
beta factor
CTLA-4 Antigen
antibodies
Transforming Growth Factor beta
Immunotherapy
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors
Izumchenko, E. , Paz, K. , Ciznadija, D. , Sloma, I. , Katz, A. , Vasquez-Dunddel, D. , Ben-Zvi, I. , Stebbing, J. , McGuire, W. , Harris, W. , Maki, R. , Gaya, A. , Bedi, A. , Zacharoulis, S. , Ravi, R. , Wexler, L. H. , Hoque, M. O. , Rodriguez-Galindo, C. , Pass, H. , Peled, N. & 4 others , 2017, In : Annals of Oncology. 28, 10, p. 2595-2605 11 p.Research output: Contribution to journal › Article
Heterografts
Neoplasms
Therapeutics
Exome
Translational Medical Research
SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells
Ozawa, H., Ranaweera, R. S., Izumchenko, E., Makarev, E., Zhavoronkov, A., Fertig, E. J., Howard, J. D., Markovic, A., Bedi, A., Ravi, R., Perez, J., Le, Q. T., Kong, C. S., Jordan, R. C., Wang, H., Kang, H., Quon, H., Sidransky, D. & Chung, C. H., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 5162-5175 14 p.Research output: Contribution to journal › Article
Head and Neck Neoplasms
Gene Knockdown Techniques
Phenotype
Cell Line
Cetuximab
Patient-derived xenografts as tools in pharmaceutical development
Izumchenko, E., Meir, J., Bedi, A., Wysocki, P. T., Hoque, M. O. & Sidransky, D., 2016, (Accepted/In press) In : Clinical Pharmacology and Therapeutics.Research output: Contribution to journal › Article
Heterografts
Pharmaceutical Preparations
Neoplasms
Decision Making
Therapeutics
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
Gilbert, J., Schell, M. J., Zhao, X., Murphy, B., Tanvetyanon, T., Leon, M. E., Hayes, D. N., Haigentz, M., Saba, N., Nieva, J., Bishop, J., Sidransky, D., Ravi, R., Bedi, A. & Chung, C. H., 2015, In : Oral Oncology. 51, 4, p. 376-382 7 p.Research output: Contribution to journal › Article
Disease-Free Survival
Neoplasms
Cytokines
Human papillomavirus 6
sorafenib